Diane J. Kalina
Präsident bei BioCatalyst Yorkton, Inc.
Profil
Ms. Diane J.
Kalina is a Managing Director at PDC Biotech GmbH and President & Director at BioCatalyst Yorkton, Inc. She is on the Board of Directors at BioCatalyst Yorkton, Inc.
Ms. Kalina was previously employed as Head-Marketing, Director-New Products & Licensing by GSK Products, Inc., Chief Financial Officer by Mexigold Corp., and President & Director by YM BioSciences, Inc. She also served on the board at Arius Research, Inc.
Aktive Positionen von Diane J. Kalina
| Unternehmen | Position | Beginn |
|---|---|---|
| BioCatalyst Yorkton, Inc. | Präsident | 01.01.2005 |
Ehemalige bekannte Positionen von Diane J. Kalina
| Unternehmen | Position | Ende |
|---|---|---|
Arius Research, Inc.
 Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | Direktor/Vorstandsmitglied | 06.12.2007 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Präsident | - |
GSK Products, Inc.
 GSK Products, Inc. Wholesale DistributorsDistribution Services Part of Princeton American Corp., GSK Products, Inc. is a beauty and barber supply concern. The company is based in Phoenix, AZ. | Vertrieb & Marketing | - |
PDC Biotech GmbH
 PDC Biotech GmbH BiotechnologyHealth Technology PDC Biotech GmbH operates as a biopharmaceutical company developing innovative therapeutics for the treatment of preterm labor and primary dysmenorrheal in women. The firm’s pipeline products include prostaglandin F2a (FP) receptor antagonists, PDC31 a synthetic octapeptide, which is designed to act as an allosteric modulator of the receptor for prostaglandin FP receptor. The company was founded by Patricia Griffin and Diane J. Kalina in May 2008 and is headquartered in Vienna, Austria. | Vorstandsvorsitzender | - |
| E3 LITHIUM LIMITED | Finanzdirektor/CFO | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| E3 LITHIUM LIMITED | Process Industries |
| Private Unternehmen | 5 |
|---|---|
Arius Research, Inc.
Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | Health Technology |
| BioCatalyst Yorkton, Inc. | |
PDC Biotech GmbH
PDC Biotech GmbH BiotechnologyHealth Technology PDC Biotech GmbH operates as a biopharmaceutical company developing innovative therapeutics for the treatment of preterm labor and primary dysmenorrheal in women. The firm’s pipeline products include prostaglandin F2a (FP) receptor antagonists, PDC31 a synthetic octapeptide, which is designed to act as an allosteric modulator of the receptor for prostaglandin FP receptor. The company was founded by Patricia Griffin and Diane J. Kalina in May 2008 and is headquartered in Vienna, Austria. | Health Technology |
GSK Products, Inc.
GSK Products, Inc. Wholesale DistributorsDistribution Services Part of Princeton American Corp., GSK Products, Inc. is a beauty and barber supply concern. The company is based in Phoenix, AZ. | Distribution Services |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
